We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Anecortave Acetate Versus Placebo in AMD Patients Following PDT

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00346866
First Posted: June 30, 2006
Last Update Posted: August 5, 2008
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
Alcon Research
  Purpose
The purpose of this study was to evaluate the efficacy of anecortave acetate for depot suspension (30 mg and 15 mg) plus PDT versus PDT alone with respect to maintenance of visual acuity in patients with wet AMD.

Condition Intervention Phase
AMD Drug: anecortave acetate Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double
Primary Purpose: Treatment
Official Title: Anecortave Acetate Versus Placebo in AMD Patients Following PDT

Further study details as provided by Alcon Research:

Primary Outcome Measures:
  • Mean change from the baseline in logMAR visual acuity score at Month 6

Secondary Outcome Measures:
  • % patients who maintained vision, number of months of angiographic evidence of needing PDT re-treatment, and mean lesion sizes for the total choroidal neovascularization (CNV) and the classic component to the total CNV.

Estimated Enrollment: 136
Study Start Date: May 2000
Study Completion Date: December 2001
Primary Completion Date: December 2001 (Final data collection date for primary outcome measure)
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   50 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • AMD disease

Exclusion Criteria:

  • Age
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00346866


Locations
United States, Ohio
Facility
Beachwood, Ohio, United States, 44122
Sponsors and Collaborators
Alcon Research
Investigators
Study Director: Patricia Zilliox Alcon Research
  More Information

ClinicalTrials.gov Identifier: NCT00346866     History of Changes
Other Study ID Numbers: C-00-07
First Submitted: June 28, 2006
First Posted: June 30, 2006
Last Update Posted: August 5, 2008
Last Verified: August 2008

Additional relevant MeSH terms:
Anecortave
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Growth Substances
Physiological Effects of Drugs
Growth Inhibitors
Antineoplastic Agents